Edesa Biotech
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.edesabiotech.com
- Introduction
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19
- Conditions
- ARDSCOVID-19
- Interventions
- Biological: SOC plus 15mg/kg EB05 IVOther: SOC plus Placebo IV
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Edesa Biotech Inc.
- Target Recruit Count
- 644
- Registration Number
- NCT04401475
- Locations
- 🇺🇸
UCSF Fresno, Fresno, California, United States
🇺🇸St. Jude Medical Center/ Providence, Fullerton, California, United States
🇺🇸University of Miami Hospital, Coral Gables, Florida, United States
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
- Conditions
- Allergic Contact Dermatitis
- Interventions
- Drug: EB01 Cream PlaceboDrug: EB01 Cream 0.2%Drug: EB01 Cream 1.0%Drug: EB01 Cream 2.0%
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Edesa Biotech Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT03680131
- Locations
- 🇺🇸
Oakland Hills Dermatology P.C., Auburn Hills, Michigan, United States
🇺🇸Apex Clinical Research Center, LLC, Mayfield Heights, Ohio, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States